Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study

BACKGROUND: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus ChAdOx1 in haemodialysis patients. METHODS: In this observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Paul, Gleeson, Sarah, Clarke, Candice L., Thomson, Tina, Edwards, Helena, Spensley, Katrina, Mortimer, Paige, McIntyre, Stacey, Cox, Alison, Pickard, Graham, Lightstone, Liz, Thomas, David, McAdoo, Stephen P., Kelleher, Peter, Prendecki, Maria, Willicombe, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463038/
https://www.ncbi.nlm.nih.gov/pubmed/36105885
http://dx.doi.org/10.1016/j.lanepe.2022.100478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463038/
https://www.ncbi.nlm.nih.gov/pubmed/36105885
http://dx.doi.org/10.1016/j.lanepe.2022.100478

Ejemplares similares